ActiGraph is a leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community. ActiGraph’s FDA-cleared wearable accelerometry monitors and robust analytics platform are widely used to capture real-world objective outcomes related to activity, mobility, and sleep behavior in clinical trials, academic research, and population studies.
BrainBaseline accelerates clinical trials via accessible and unrivaled mobile measurement. Our solution assesses in-context patient behavior, cognition, health, and quality of life via engaging consumer applications—all while securely managing data via our GCP-compliant platform. To date, BrainBaseline has been deployed in over 1,500 studies.
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
Loss of mobility is a growing unmet need. FeetMe for the first time in the world will be the trustworthy partner for mobility specialists and patients to improve mobility with smart active wearables and collect key objective information to make life impacting therapeutic decisions.
Granted Breakthrough Status by the FDA. nQ is a computational biotechnology company that has digitally phenotyped neurodegenerative diseases through AI-aided analysis of passively collected data from personal device interactions. It has digital biomarkers for AD/MCI and PD and it is finalizing development of same for MS, ALS, and mTBI with industry partners and academic centers including Cleveland Clinic and Massachusetts General Hospital.
In prodromal stages of neurodegenerative diseases, digital biomarkers can detect subclinical symptoms known to predict phenoconversion better than biochemical markers which often predict disease risk but not timing. nQ’s biomarkers are used for early detection, remote, RWE tracking of disease progression, and measurement of therapeutic effectiveness.
VivoSense is an agile end to end solutions company measuring patient outcomes by developing novel digital endpoints from wearable sensor data. VivoSense is focused on healthcare research & delivery, clinical trials and patient wellness. Our hypothesis-driven framework provides analytical and clinical validation leading to FDA approval.
The Digital Medicine Society (DiMe) is the professional society for the digital medicine community. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health.
The Digital Biomarkers & Digital Measurements Summit Goes Online for 2020
With Digital Biomarkers / Measurements hotter than they’ve ever been, the need to meet and learn is greater than it’s ever been. Therefore, we cannot afford to put things on hold.
The Digital Biomarkers & Digital Measurements Summit has been completely re-engineered to deliver the best networking experience together with exciting new learning opportunities.
Replicate those all-important ‘water cooler’ moments through randomly assigned networking or join custom-built sessions to find those with similar interests to you. Scroll through the entire attendee list to message your fellow attendees, schedule 1-2-1 video calls, or create your own private session rooms for group discussions. The Digital Biomarkers & Digital Measurements Summit will enable you to meet more leaders from across the industry than ever before!
The agenda is purposely built to provide an engaging and interactive learning experience. Through integrated polls, open discussions, Q&A with speakers, and more, you will be able to accelerate your knowledge of the Digital Biomarkers / Measurements in just two days. The ability to actively or passively be involved in these learning opportunities is yours!
The Digital Platform lets you create your own personal agenda. You can attend live sessions, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job. All of this from the comfort of your own home.
The Digital Biomarkers & Digital Measurements Summit has taken a practical approach to build a baseline of knowledge. The event covers foundational concepts like digital measures, biomarkers, regulatory pathways, IoMT security and data rights. Not to be missed!
Digital Biomarkers & Digital Measurements Summit is ideally timed to enable critical conversations between stakeholders enabling the progression of medicine toward a patient-oriented, decentralized, tech-enabled future.
Digital measurements offer the potential to transform how we define health and revolutionize how we care for patients and conduct biomedical research. The Digital Biomarkers & Digital Measurements Summit is the first event dedicated to advancing this vision. Join us!
I am very excited to be part of the Digital Biomarkers & Digital Measurement Summit. This great virtual meeting will bring together experts on digital health from around the world. I highly recommend this event to anyone interested in the new age of health
Dr. Ray Dorsey is the David M. Levy Professor of Neurology and Director of the Center for Health + Technology at the University of Rochester. The Center seeks to provide care and research opportunities to anyone anywhere. Ray and his colleagues have written Ending Parkinson’s Disease, a book that provides a prescription for ending this debilitating condition.
Ray previously directed the movement disorders division and neurology telemedicine at Johns Hopkins and worked as a consultant for McKinsey & Company. His research has been published in leading medical, neurology, and economic journals and has been featured on National Public Radio, in The New York Times, and in The Wall Street Journal. In 2015, the White House recognized him as a “Champion for Change” for Parkinson’s disease.
Andy Coravos (@andreacoravos) is the CEO/co-founder of Elektra Labs, building a digital medicine platform focusing on digital biomarkers for decentralized clinical trials. Formerly, she served as an Entrepreneur in Residence at the FDA working in the Digital Health Unit (DHU). She serves on the Board of the Digital Medicine Society (DiMe), and she’s an advisor to the Biohacking Village at DEF CON.
At Mass General Brigham, Dr. Joe Kvedar has focused on driving innovation, creating the market and gaining acceptance for connected health for nearly three decades. He is now applying his expertise, insights and influence to advancing adoption of telehealth and virtual care technologies at the national level.
He is Professor of Dermatology at Harvard Medical School, President Elect of ATA (The American Telemedicine Association), Co-Chair of the AMA’s Digital Medicine Payment Advisory Group and Editor-in-Chief of npj Digital Medicine, a Nature Research journal.
He is the author of two books on digital health: The Internet of Healthy Things (2015) and The New Mobile Age: How Technology Will Extend the Healthspan and Optimize the Lifespan (2017). The cHealth Blog provides his insights and vision for digital health.
Dr. Kvedar is advisor to and serves on the board of a number of Venture Capital Firms and digital health companies.
Peter R. Bergethon, M.D. is Vice President and Head of Digital and Quantitative Medicine (DQM) at Biogen. He leads the identification of technologies and methodologies that transform drug development. DQM creates value by leading the transition of clinical practice in Biogen’s core and emerging growth areas from a qualitative to a quantitative discipline, and connecting the Clinical with the Research enterprise, to advance therapeutics and personalized medicine.
Peter came to Biogen in 2017 from Pfizer Worldwide Research and Development where he was Vice President and Head of the Pfizer Innovation Research Lab within the Early Clinical Development group. At Pfizer, Peter led both the Quantitative Medicine group and the Innovation Research Labs where he pioneered mobile and digital clinical assessment technology, human neurophenotyping, and multi-modal data analytics to accelerate clinical development in neuroscience, immunology, rare diseases, and cardiometabolic disease.
He is an accomplished clinical neurologist and neuroscientist who, prior to joining Pfizer, was a Professor at Boston University and Tufts University in the Departments of Biochemistry, Neurology, Neurobiology & Anatomy, and Biomedical Engineering.
Rhoda Au is Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University Schools of Medicine and Public. She also serves as Director of Neuropsychology at the Framingham Heart Study, is using technologies to develop digital cognitive biomarkers. Her current interest focus on building multi-sector ecosystems to enable solutions that move the primary focus of health technologies from precision medicine to a broader emphasis on precision brain health.
Dr John Whang is currently Head, Integrated Evidence in Cardiovascular and Metabolism at Janssen Pharmaceuticals. In this role, he aligns the development, interpretation, and dissemination of evidence – randomized, real-world, and health economic – to support products throughout their lifecycle in the multi-stakeholder health care customer environment.
Previous roles include Executive Director, US Medical Affairs, Amgen; President, Real Endpoints; consultant at McKinsey&Co.; and attending cardiologist, Morristown Medical Center.
John is a graduate of Harvard College and the Vagelos College of Physicians and Surgeons, Columbia University.
Dr. Vaziri is a Co-Founder and CEO of BioSensics, a biomedical firm focused on development of wearable sensors and digital technologies for clinical trials and health outcome assessments. Prior to joining BioSensics in September 2019 as its CEO, Dr. Vaziri was a tenured Professor of Engineering at Northeastern. Dr. Vaziri has authored 150+ journal papers, 250+ conference proceedings, and has served as a PI or Key Investigator on over 20 industrial, national and international grant awards.
Rachel Sha is the Vice President of Digital Business Development & Licensing at Sanofi. She leads a team of business development professionals in partnering, from identification to closing, across therapeutic areas and use cases in digital health with the goal of discovering, developing, and bringing to market solutions that improve outcomes, experience, at reduced costs. Companies she has led partnering deals with in digital include Verily Life Sciences, Science 37, and Evidation Health. Additionally, she serves on the Life Sciences Council of Springboard Enterprises which is focused on supporting women-led companies to grow and expand.
She joined Genzyme in 2005 and has held roles of increasing responsibility in Business Development, Corporate Development, and Global Marketing & Strategy for Genzyme and Sanofi. Prior to Sanofi, Genzyme, Rachel was a manager at Accenture where she focused on a broad range of business issues from strategy to process to technology implementation. Rachel holds a BS from Massachusetts Institute of Technology in Chemistry and an MBA from Harvard Business School.
Vaibhav is currently Vice President and Head of Data Science for the Neuroscience Therapeutic Area. In this role, Vaibhav is responsible for applying advanced analytics to genetic, molecular, clinical and digital phenotyping data to gain disease insights, discover novel drug targets and enable precision and predictive medicine strategies in Neuroscience. Vaibhav has pioneered use of data derived from wearable sensors and smartphones to develop digital biomarkers for early detection, disease progression, drug response, treatment monitoring and relapse prediction in Alzheimer’s, Mood and Schizophrenia.
Vaibhav joined Johnson and Johnson from Eli Lilly and Co., where he was the Head of Discovery and Medical Informatics group. Prior to Lilly, Vaibhav held multiple leadership roles in bioinformatics and genomics start-up companies, including Celera Genomics where he participated in the sequencing, assembly and analysis of the human genome.
Vaibhav obtained his PhD from Yale University in Computational Biology in 1998 and an Executive MBA from Kellogg School of Management, Northwestern University in 2009.
Dr Massé obtained his doctorate degree at the Ecole Polytechnique Fédérale de Lausanne (EPFL/Switzerland) from the Laboratory of Motion Analysis and Measurement (LMAM).
Lauren Li is Head of Digital Health at Ipsen, a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience, and Rare Diseases. Driven by a passion to improve the access to and quality of care around the world, she works at the intersection of life sciences and technology, leading a team to create “beyond the drug” solutions. Prior to Ipsen, she held multiple biotech commercial roles at Amgen both in the U.S. and in Europe, spanning digital innovation, analytics & insights, marketing, and sales. Lauren also formerly led strategy and operations at Princess Margaret Cancer Centre – a top 5 academic cancer hospital in the world, consulted at McKinsey & Company, and ran a successful family business. She holds an M.B.A. from Harvard Business School and a B.A. with honors in economics from Princeton University.
Dr Karlin is the CEO and the co-founder at HealthMode.com. He was previously the Head of Clinical, Informatics, and Regulatory Strategy for Digital Medicine at Pfizer, having passed through a number of roles on the way to this position including Senior Director, Quantitative Medicine, Group Lead for Human Biology and Medical Informatics with Pfizer’s Neuroscience Research Unit in Cambridge, MA. He is an Assistant Professor at Tufts Medical Center in Boston, and had been the Director of Psychiatry Informatics, and the Associate Training Director for Psychiatry. His primary research interests are neuropsychiatric drug development, medical informatics, cognition in clinical medicine, and methods for medical education, especially as these relate to decision-making strategies used by medical professionals. In addition, Dr Karlin is actively involved in designing and implementing information systems and resources for clinical and research use. Dr Karlin trained in Psychiatry at Tufts Medical Center, attended medical school at the University of Colorado School of Medicine, and graduate school for Clinical Informatics and Cognitive Science as well as undergraduate studies in Neuroscience and Behavior at Columbia University. He is board certified in Psychiatry, Addiction Medicine, and Clinical Informatics.
Jamileh Jemison (she/her), Head of Clinical Development, HealthMode is a physician-scientist with specialty training in genetics and pediatrics, who has led clinical research in oncology, opioid use disorder, autism, and autoimmune disorders. JJ worked in clinical operations and development at Boston Biomedical Inc., Finch Therapeutics, HealthCore, and Pear Therapeutics before joining HealthMode in 2019.
Nina is the Executive Director of the Biohacking Village at DEF CON and has worked in healthcare tech/sec for 16 years, primarily in Electronic Medical Record and connected IoT medical devices. Nina worked as a Scientist in Residence at the New York Academy of Sciences and has served in the US Marine Corps.
Kimon Angelides is the founder of four healthcare companies: Vivante, EsoHealth which became Livongo, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment models, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals. His newest company, Vivante Health, formed in late early 2016, tackles digestive health.
Kimon recently received the digital health Founder of the Year Award from Rock Health, Goldman Sachs, and PacWest Bank for his contributions and work in digital medicine. Kimon is keen on bringing digital technologies to those who have fallen through the cracks in the healthcare system and with difficult to diagnose and treat conditions. He views these technologies as an opportunity to bring together multiple disciplines including digital therapeutics, diagnostics and discovery medicine, devices, and predictive analytics, all directed toward enhance outcomes.
Prior to his healthcare career, Kimon was Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK building the pre-clinical services for the new medical school, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kimon has served on the National Medical Advisory Boards of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kimon was Research Career Development Award from the NIH, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 40 patents. He received a PhD in Chemistry from the University of California and has done graduate study in business, laws, and public health.
Dr. Chelsea Trengrove has 5+ years of experience in international program management, business development, consulting, speaking, and regulatory guidance in the pharmaceutical and medical device industries. A Ph.D. with strong foundations in neuroscience and pharmacology research, she joined Empatica’s team as a program manager just prior to their FDA clearance in 2018 for their seizure monitoring and alerting wearable device. At Empatica, Chelsea guides biotechnology companies through the framework, science, and applications of Empatica’s wearable technologies, as well as the coordination of research initiatives, and clinical trials using Empatica’s Embrace and E4 devices from ideation to execution.
Dr. James Musick is VP and Head of Digital Transformation at UCB Biopharma where he is responsible for introducing digital transformation strategies and capabilities in order to amplify UCB’s mission of improving lives of people living with severe disease. He does this by creating focused, and integrated, therapeutic area health tech and digital engagement strategies, creating the teams and coaching the individuals who then lead key transformation projects to achieve the strategy while developing the digital culture and capabilities to sustainably advance the organization to digital maturity.
Prior to joining UCB, Dr. Musick was at Novartis leading the Digital Medicines Commercial team – his team designed, developed, integrated and prioritized digital health projects across six therapeutic areas, globally. These efforts resulted in removing several intractable hurdles to effective progress on digital health projects, and a cohesive shift from using marketing centric KPIs in digital health to focusing on outcomes and health system economic value as the key indicators of project success.
Before his digital health focus, Dr. Musick led digital strategy, marketing and communications teams for 10 years at large biotech and pharmaceutical companies – driving a shift to user-centric project approaches and data driven decision making.
Dr. Musick earned his B.S. in genetics and Ph.D. in neurophysiology, followed by several years working in software engineering teams, creating a data and analytics startup, and along the way receiving awards for exceptional quality digital projects.
Beau Woods is a Cyber Safety Innovation Fellow with the Atlantic Council, a leader with the I Am The Cavalry grassroots initiative, Founder/CEO of Stratigos Security, and sits on the board of several non-profits. His work bridges the gap between the security research and public policy communities, to ensure connected technology that can impact life and safety is worthy of our trust. He formerly served as Entrepreneur in Residence with the US FDA, and Managing Principal Consultant at Dell SecureWorks. Over the past several years in this capacity, he has consulted with the energy, healthcare, automotive, aviation, rail, and IoT industries, as well as cyber security researchers, US and international policy makers, and the White House. Beau is a published author, frequent public speaker, often quoted in media, and is often engaged for public or private speaking venues.
Nirmal Keshava is Vice-President of Data Science and Innovation at Cerevel Therapeutics, LLC, a new company formed by Bain Capital to develop new therapies for neurology and psychiatry. Previously, he was with AstraZeneca, where he developed novel clinical and pre-clinical approaches for using data and informatics in drug R&D. Before that he was with MIT Lincoln Labs and Draper Laboratory, leading efforts in biomedical data science and advanced sensing. He was a co-PI on multiple government-funded efforts in neuroscience and psychology focusing on TBI, PTSD, CTE, and cognitive stress. He received his B.S. and Ph.D. in electrical engineering, respectively, from UCLA and Carnegie Mellon University.
Jennifer C. Goldsack co-founded and serves as the Executive Director of the Digital Medicine Society (DiMe), a 501(c)(3) non-profit organization dedicated to advancing digital medicine to optimize human health. Jen’s research focuses on applied approaches to the safe, effective, and equitable use of digital technologies to improve health, healthcare, and health research. She is a member of the Roundtable on Genomics and Precision Health at the National Academies of Science, Engineering and Medicine.
Previously, Jen spent several years at the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by Duke University and the FDA. There, she led development and implementation of several projects within CTTI’s Digital Program and was the operational co-lead on the first randomized clinical trial using FDA’s Sentinel System.
Jen spent five years working in research at the Hospital of the University of Pennsylvania, first in Outcomes Research in the Department of Surgery and later in the Department of Medicine. More recently, she helped launch the Value Institute, a pragmatic research and innovation center embedded in a large academic medical center in Delaware.
Jen earned her master’s degree in chemistry from the University of Oxford, England, her masters in the history and sociology of medicine from the University of Pennsylvania, and her MBA from the George Washington University. Additionally, she is a certified Lean Six Sigma Green Belt and a Certified Professional in Healthcare Quality. Ms Goldsack is a retired athlete, formerly a Pan American Games Champion, Olympian, and World Championship silver medalist.
Richie Bavasso is CEO and co-founder of nQ Medical Inc, a machine learning computational biomarker company leveraging personal devices to manage neuromotor diseases. nQ builds powerful, AI solutions to support the continuum of brain health. This MIT discovered/Michael J. Fox Foundation validated artificial intelligence tool (neuroQWERTY) has opened a broad opportunity to better diagnose diseases, track disease progression, and monitor medication effectiveness and symptoms.
He is also Senior Executive Consultant, Digital Health and MedTech, Americas, for Scottish Development International. In this role, he supports the Scotland Government advising and assisting Scottish life sciences, MedTech, and digital health start-ups with expansion into the US market.
Carrie Northcott, PhD is a Director/Project Lead within the Digital Medicine and Translational Imaging (DMTI) group in Early Clinical Development (ECD) at Pfizer, located in Cambridge, MA. She leads a diverse team that is evaluating and implementing the use of wearable digital devices to more fully understand and characterize physiological endpoints, such as nighttime scratch and sleep. Carrie has a diverse scientific background in Pharmacology, Toxicology, and Physiology which provides unique insight into understanding how these endpoints provide meaningful information to patients, doctors and researchers to better treat and understand diseases.
Dr. Ghaffari graduated from MIT with BS and MEng degrees in Electrical Engineering and received his PhD in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology. Dr. Ghaffari is currently Director of Translational Research at Northwestern University’s Querrey Simpson Institute for Bioelectronics and is Research Associate Professor in the Department of Biomedical Engineering. In 2017, Dr. Ghaffari co-founded and has served as CEO of Epicore Biosystems, a health solutions company commercializing ambulatory wearable microfluidic devices for tracking health and hydration biomarkers. Prior to Epicore Biosystems, Dr. Ghaffari co-founded and served as CTO of wearable health technology company, MC10, where he led the development and launch of the BioStamp Wearable System for tracking movement disorders in remote clinical trials. His contributions in soft bioelectronics, biosensors, microfluidics and neuroscience have been recognized with the MIT100K Grand Prize, IEEE Spectrum Emerging Technology Prize, and the MIT Technology Review Magazine’s Top 35 Innovators Under 35. He has published over 90 academic papers and is inventor on over 50 patents issued.
Ninad Gujar joined NeuroLogica in 2014, leading the Regulatory and Quality team. Dr. Gujar has held key leadership positions in organizations working at the intersection of technology and healthcare with responsibility for activities supporting product adoption and value creation. Dr. Gujar has led the development and execution of worldwide regulatory strategy, domestic and international registrations, implementation and monitoring of quality management system and compliance activities. Prior to joining Samsung, Dr. Gujar worked in management consulting for portfolio medical device companies in areas ranging from market research, product strategy, business development and regulatory affairs. Dr. Gujar is an active member of the healthcare innovation and entrepreneurship community, helping mentor startups at incubators and universities.
Dr. Gujar earned a Bachelor of Engineering from University of Pune, a Master of Science in Biomedical Engineering from University of Texas at Arlington, a MBA from Babson College and received his Ph.D. degree from University of West London.
Matteo Lai is co-founder and CEO of Empatica, a digital biomarker and medical devices company based in Boston, Massachusetts and Milan, Italy. Empatica provides an end-to-end remote health monitoring platform for running decentralized clinical trials, and develops digital biomarkers that can monitor a range of conditions. As a technology entrepreneur, Mr. Lai contributed to the invention of the solutions being offered by Empatica. The company has developed the award-winning Embrace; the world’s smallest and most accurate wearable sensor suite for research, which also became the world’s first FDA cleared smart watch for use in Neurology. Matteo studied Engineering, trained as an Architect, and holds a Double MSc degree in Architecture and a Master in Innovation Management. He was recently selected by Sifted as one of the top pioneers of the European start-up world.
Following his studies at Ecole Polytechnique and UC Berkeley, Alexis has identified unmet clinical needs within rehabilitation. Alexis has built a team of engineers, physicians, designers with broad expertise, ranging from physics to signal processing and biomechanics. He has set up a strong tech culture, including a focus on testing.
Adam is the Vice President of Technology Partnerships at Kaia Health, a digital therapeutics company that creates treatments for a range of musculoskeletal disorders. Adam leads the strategic development of Kaia’s computer vision technology, which is used to guide exercise and assess movement patterns remotely. Adam’s graduate research at Stanford University’s Neuromuscular Biomechanics Lab focused on leveraging AI and modern sensors, such as wearables and mobile cameras, to analyze human movement.
Dr. Shyamal Patel leads the data science team in the Digital Medicine & Translational Imaging group at Pfizer. Dr. Patel’s work is focused on leveraging wearable and connected technologies for developing, validating and deploying novel digital endpoints with the goal of making clinical trials more objective and efficient. His work has resulted in the deployment of novel digital endpoints in multiple clinical trials across neurology, oncology, rare diseases, immunology and inflammation.
Dr. Kate Papp is an Assistant Professor of Neurology at Harvard Medical School. She works as a Clinical Neuropsychologist in the Department of Neurology at the Brigham and Women’s Hospital and the Massachusetts General Hospital. She serves as the Lead Neuropsychologist and the Co-Leader of the Outcomes Core for the Alzheimer’s Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). She is a member of the Cognitive Outcome Instrument Unit of the Alzheimer’s Clinical Trial Consortium (ACTC). She is an investigator in the Clinical Core of the Harvard Aging Brain Study, a longitudinal cohort study of normal older adults with annual cognitive testing in addition to multimodal imaging (including amyloid and tau PET).
She has worked in the development and validation of digital measures of cognitive performance for the preclinical Alzheimer’s disease population including implementing computerized testing using the C3 in Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4). She more recently received a Pilot Award Grant from the Massachusetts Alzheimer’s Disease Research Center to further develop the mobile-based testing of memory with the Boston Remote Assessment for Neurocognitive Health (BRANCH). She is funded by the National Institute on Aging and the Alzheimer’s Association.
Manny is a physician with a background in biomedical engineering and an interest in the evolving role of digital biomarkers in research and care delivery. He is a current Harvard HealthTech Fellow and hospitalist at the West Roxbury VA, and a member of the strategic advisory board at ElektraLabs. Prior to coming to Boston, he completed a residency in Internal Medicine at the University of Pennsylvania.
Dr. Dias is a physician-scientist and an Instructor at the Department of Emergency Medicine at Harvard Medical School. He leads the Human Factors & Cognitive Engineering lab at the STRATUS Center for Medical Simulation, Brigham and Women’s Hospital and his research focuses on the application of cutting-edge technologies, such as artificial intelligence, machine learning and digital biomarkers to assess and enhance clinicians’ performance and improve patient safety in a variety of high-risk high-stakes settings, including emergency medicine, critical care, surgery, and space medicine.
Dr. Dias was trained in Internal Medicine and Emergency Medicine at the University of Sao Paulo Medical School, in Brazil and earned a Ph.D. in Medical Sciences and an M.B.A in Hospital and Health Systems Administration. He also completed a postdoctoral research fellowship at Harvard Medical School, developing research in medical simulation, human factors, non-technical skills, and wearable sensors.
Marcee Chmait has served in multiple rolls within the healthcare industry for nearly 30 years. Her passion is to innovate, incubate and develop new businesses and to grow them into meaningful businesses. Marcee has spent her career at the brink of healthcare innovation, identifying opportunities to merge direct relationships between consumer and provider before consumer-centered healthcare was even a strategy.
In January 2018, Marcee joined Providence St. Joseph Health to lead commercialization for the Digital Strategy and Innovation Group. In this role, Marcee is working to bring consumer-facing technology solutions to health systems to improve the consumer experience within health systems. Prior to Providence, Marcee led innovation at SCAN Health Plan, a Medicare Advantage health plan in southern California.
In April 2013, Marcee joined Cambia Health Solutions as President of SpendWell. SpendWell’s mission is to transform the U.S. health system by introducing a simple way for people to shop, pay and receive health care services at a fair market price while simplifying health care payments to providers. SpendWell was a cornerstone business to the broader retail enablement pillar at Cambia.
Marcee is a serial entrepreneur. SpendWell is her third startup company. eBenx and HealthAllies had successful exits as one went public and their other was acquired by UnitedHealthcare. Marcee is a graduate from the University of Minnesota with a degree in Marketing Communications.
Pavan Choksi is an Investment Associate at Arkitekt Ventures, an early stage healthcare venture fund based in New York City that specializes in investments in novel models of healthcare delivery including digital therapeutics and applications of frontier technology such as artificial intelligence, augmented reality, genomics, and brain machine interfaces to medicine.
Prior to Arkitekt, he was the first employee and Vice President of Corporate Development for Rx.Health, a venture-backed Mount Sinai Health System spin-off commercializing a novel Digital Medicine prescription and delivery platform. As an active member of the digital health ecosystem, he serves as Strategic Advisor to the Digital Therapeutics Alliance and NODE Health.
Jeremy Wyatt is CEO of ActiGraph, a leading global provider of activity and sleep monitoring solutions for pharmaceutical and academic industries. Jeremy has 20 years of experience with low-power micro-electro-mechanical systems and related cloud technology, giving him a unique perspective on challenges and opportunities of deploying wearable technology to produce meaningful patient data.
With over 15 years’ experience in clinical and academic research, Dr Jenny Barnett is responsible for leading Cambridge Cognition’s ground-breaking R&D as Chief Scientific Officer. Dr Barnett is also an Honorary Research Fellow at the University of Cambridge, a team member of the Northern Finland Birth Cohorts, and Chief Executive Officer at Monument Therapeutics.
Joan Severson, CEO, has grown BrainBaseline into a leader in remote clinical sensing, with a premium on monitoring, measuring, and quantifying patients in their natural environment. Her interests include advanced sensing, GIS, neuropsychology, and human factors. She earned a BA and MS in computer science from the University of Iowa.
Joan will be joined by Josh Cosman, Director of Digital Health Strategy at AbbVie.
Paul Dagum, MD, PhD is an entrepreneur, physician and computer scientist with a track record of bringing product, technology and business model innovation into healthcare, cybersecurity and supply chain through four successful venture-backed companies as founder, CSO, CTO and CEO.
Dr. Dagum’s early pioneering research in dynamic Bayesian networks is in use in many modern-day applications. He further developed and patented massively scalable algorithms for big data science in use by the world’s largest data companies, created and patented the first digital measures of brain function from human-computer interactions captured passively from a mobile device, and designed a novel care model for mental health built on a foundation of continuous measurement and AI informed telehealth services. Dr. Dagum led NSF and NIH grants while at Stanford University, published over 75 peer-review articles and book chapters in computer science and medicine, and was awarded over 25 patents.
Dr. Dagum received an MSc in theoretical physics, PhD in theoretical computer science both from the University of Toronto and an MD and surgical residency training at Stanford University.
Dr Francesca Cormack has extensive experience of statistics, cognitive neuroscience and cognitive test development in a range of clinical populations. Since joining Cambridge Cognition in 2014, Dr Cormack has worked to develop novel cognitive testing methodology to support high-frequency, near patient testing using digital technology, providing researchers and healthcare providers with unique insights into cognitive health.
Dr Cormack obtained a PhD in Dementia with Lewy Bodies at Newcastle University, followed by post-doctoral and academic positions at University College London and at the Medical Research Council in Cambridge. She maintains academic collaborations focused on neurological disorders, ageing and dementia.
Digital Conference Platform
The Digital conference platform is purpose-built to enable us to provide you with a more personal experience.
For starters, no more wondering who is in the room! View and message the entire attendee list. If that’s not enough, there are a multitude of structured and unstructured networking opportunities to give you the chance to reconnect with old friends and meet your future collaborators.
Then there’s the learning. Through an engaging and interactive agenda, you will be able to actively or passively participate as much as you’d like. From polls and Q&A through to open discussions and dynamic panels, it has never been easier to accelerate your knowledge of Digital Biomarkers / Measurements.
Imagine the possibilities of this digital event! Networking with your peers, learning from the experts, collaborating, and shaping the future of The Digital Biomarkers / Measurements industry – all on a world-class, purpose-built platform.
Partner with Us
The Digital Biomarkers & Digital Measurements Summit being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together the senior R&D exec’s from across digital health, pharma, healthcare, investors and beyond.
Making your session engaging and knowledgeable will attract the largest audience. We will guide you on how best to maximize the benefits of using our platform.
No need to sit behind a desk! Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.
Get in touch to learn more about the options available at The Digital Biomarkers & Digital Measurements Summit.
Register for the Event
For pricing and booking options please click the button to go to the registration page.